KR101923603B1 - A composition for anti-obesity comprising green tea complex extracts - Google Patents

Abstract

The present invention provides an anti-obesity composition comprising a complex extract consisting of a green tea extract, a mate extract, and an Atractylodes japonica extract; and a Cinnamomum cassia extract as active ingredients. According to the present invention, the anti-obesity composition is excellent in preventive and therapeutic effects against obesity-related compensatory diseases such as stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease or non-alcoholic fatty liver.

Description

A COMPOSITION FOR ANTI-OBESITY COMPRISING GREEN TEA COMPLEX EXTRACTS < RTI ID = 0.0 >

The present invention relates to an anti-obesity composition comprising green tea extract, mote extract, chrysanthemum extract and broiler chick extract as active ingredients.

Obesity is a state of excessive accumulation of body fat that has a detrimental effect on health. When the amount of calories consumed by the food is greater than the calories consumed by physical activity, it accumulates in body fat. A man is said to be overweight when body fat is over 25% of body weight, and when a woman is over 30% of body weight.

The causes of obesity are diseases and genetic factors such as hypothalamic function and energy metabolism abnormality, but most obesity is caused by lifestyle due to excessive nutrition and decrease of physical activity. In recent years, due to the western eating habits and the convenience of living, the incidence of obesity is continuously increasing due to an increase in the intake of instant food and lack of exercise, and it is expected that this tendency will further increase with time.

The biggest problem of obesity is the problem of causing various metabolic diseases such as diabetes, hyperlipemia, heart disease, stroke, arteriosclerosis, fatty liver and adult diseases which are caused by a long time duration of obesity rather than simple obesity itself. Obesity also increases the risk of various diseases such as infertility, menstrual irregularities, degenerative arthritis, some cancers, sleep apnea, respiratory disorders, gallstone disease and depression, and it is emerging as a social problem and a risk factor of adult diseases.

Recently, by recognizing obesity as a disease, various pharmaceutical companies are accelerating the development of drugs that treat obesity. Xenical (Roche Pharmaceuticals, Switzerland), a fat absorption inhibitor, is one of the world's most widely used treatments for obesity. The orlistat, a component of the genicide, binds to digested fat and inhibits absorption in the intestines, thus excreting some of the fat in the diet. Other drugs developed include Reductil (TM) (Abbott, USA), which promotes satiety, and Exolise (Atolpha, France).

However, the commercialized drugs are reported to have side effects such as liver damage, gastrointestinal bleeding, inflammatory bowel disease, kidney stones, and are at risk of heart, respiratory or neurological diseases.

Therefore, in the case of using a commercialized obesity treatment agent, it is required to develop a medicine having excellent side effects such as the above-mentioned stability and the effect of improving obesity with few side effects.

Korea Patent Publication No. 2007-0009562 Korean Patent Publication No. 2007-0019395

Disclosure of Invention Technical Problem [8] Accordingly, the present invention has been made to solve the above problems of the prior art, and it is an object of the present invention to provide an anti-obesity use of a natural mixed extract which is applied to long-

According to one aspect of the present invention, there is provided a combination extract comprising green tea extract, mote extract, and extracts; And a broiler chick extract as an active ingredient.

In one embodiment, the combined extract of the anti-obesity composition can be hydrothermally extracted at 60 ° C to 120 ° C.

In one embodiment, the broiler extract of the anti-obesity composition can be extracted with an alcoholic solvent.

In one embodiment, the alcoholic solvent of the anti-obesity composition may be selected from the group consisting of an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms.

In one embodiment, the combined extract of the anti-obesity composition may comprise 8.0 to 40.0 parts by weight of green tea extract, 8.0 to 40.0 parts by weight of mate extract, and 1.0 to 5.0 parts by weight of the resulting extract.

In one embodiment, the anti-obesity composition may comprise 1.0 to 5.0 parts by weight of the broiler extract.

According to another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of obesity-related metabolic diseases comprising the above-mentioned anti-obesity composition.

In one embodiment, the obesity-related metabolic disorder can be stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease, or nonalcoholic fatty liver.

According to another aspect of the present invention, there is provided an anti-appetite pharmaceutical composition comprising the anti-obesity composition.

According to another aspect of the present invention, there is provided a health functional food for preventing and ameliorating an obesity-related metabolic disease comprising the above-mentioned anti-obesity composition.

According to another aspect of the present invention, there is provided an appetite-suppressing health functional food comprising the anti-obesity composition.

According to the present invention, the anti-obesity composition is excellent in prevention and treatment of obesity-related diseases such as stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease or non-alcoholic fatty liver disease.

The anti-obesity composition can suppress the increase in body weight due to the high-calorie diet and effectively inhibit the increase of blood triglycerol and blood cholesterol.

It should be understood that the effects of the present invention are not limited to the effects described above, but include all effects that can be deduced from the description of the invention or the composition of the invention set forth in the claims.

BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph showing the weight gain inhibitory effect of the present anti-obesity composition for 12 weeks in an obesity-induced mouse model. FIG.
Normal group was fed normal diet with 10% of total calories as fat for 12 weeks and control group was fed with high fat diet with 60% of total calories as fat for 12 weeks. GB001 was orally administrated once daily with the anti-obesity composition of the present invention and the same high fat diet as that of the control group was fed for 12 weeks.

As used herein, the terminology used herein is intended to encompass all commonly used generic terms that may be considered while considering the functionality of the present invention, but this may vary depending upon the intent or circumstance of the skilled artisan, the emergence of new technology, and the like. Also, in certain cases, there may be a term selected arbitrarily by the applicant, in which case the meaning thereof will be described in detail in the description of the corresponding invention. Therefore, the term used in the present invention should be defined based on the meaning of the term, not on the name of a simple term, but on the entire contents of the present invention.

Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Terms such as those defined in commonly used dictionaries are to be interpreted as having a meaning consistent with the contextual meaning of the related art and are to be interpreted as either ideal or overly formal in the sense of the present application Do not.

The numerical range includes numerical values defined in the above range. All numerical limitations of all the maximum numerical values given throughout this specification include all lower numerical limitations as the lower numerical limitations are explicitly stated. All the minimum numerical limitations given throughout this specification include all higher numerical limitations as the higher numerical limitations are explicitly stated. All numerical limitations given throughout this specification will include any better numerical range within a broader numerical range, as narrower numerical limitations are explicitly stated.

When an element is referred to as "comprising ", it means that it can include other elements, not excluding other elements unless specifically stated otherwise.

Various scientific dictionaries, including the terms contained herein, are well known and available in the art. Although any methods and materials similar or equivalent to those described herein are found to be used in the practice or testing of the present application, some methods and materials have been described. It is not intended that the invention be limited to the particular methodology, protocols, and reagents, as they may be used in various ways in accordance with the context in which those skilled in the art use them. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS The present invention will now be described with reference to the accompanying drawings.

According to one aspect of the present invention, there is provided a combination extract comprising green tea extract, mote extract, and extracts; And a broiler chick extract as an active ingredient.

The above-mentioned " anti-obesity " means improving the symptoms of obesity. The obesity means a state in which the fat cells multiply and differentiate in the body due to metabolic disorders and thus the body fat is accumulated excessively.

The body fat refers to the fat tissue constituting the body and widely distributed around the subcutaneous tissues, the mammary gland, and the kidney, and is used as energy for storage fat, and also has built-in protection and temperature control function. The excess accumulation of storage fat is called obesity. In obesity, the amount of body fat is more important than weight in terms of prevention of complications.

The " improvement " refers to all the actions of suspected obesity and symptom improvement of the subject using the composition, and the anti-obesity composition is excellent in improving triglycerol and cholesterol levels of liver and plasma.

The obesity-related metabolic diseases are accompanied by obesity-related metabolic diseases. The obesity-related metabolic diseases include, but are not limited to, stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease or non-alcoholic fatty liver.

The above-mentioned " comprising as an active ingredient " is intended to inhibit the synthesis of, for example, triglyceride causing obesity, which may exhibit an anti-obesity effect and includes an effective amount to such an extent as to improve blood lipid concentration, It can mean to do.

The above-mentioned "green tea" is a plant leaf of Camellia sinensis belonging to the tea plant family. Currently, it is cultivated in more than 50 countries such as Africa, South America and Oceania, mainly in Asia.

The green tea contains one or more active ingredients including a polyphenolic compound catechin as one of the proven plants having excellent antioxidant ability, and is used as a drink or as a diet food or cosmetic. In addition, the green tea is known to exhibit various pharmacological actions and exhibit antioxidative action, anticancer activity, blood lipid lowering action in cardiovascular, and blood circulation promoting action.

The catechins contained in the green tea increase energy consumption and fat oxidation in the body and suppress the appetite, so that the obesity can be improved by ingesting green tea. In addition, since green tea reduces cholesterol associated with cardiovascular disease, regular intake of green tea can prevent complications caused by obesity.

The above-mentioned " Ilex paraguariensis " is a plant of about 6 m in height belonging to a subtropical plantation origin of the subtropical highlands of Brazil, Paraguay, Uruguay and Argentina. The leaves of the mate are drunk by car. The leaves contain caffeine and are widely consumed in South America. Since the mate grows in a soil rich in minerals such as calcium and iron, it contains a large amount of minerals such as iron, calcium and magnesium. In particular, the iron has a very high iron content and has an iron content of five times that of green tea leaves .

The mate has a function of lowering the appetite by allowing a feeling of fullness during drinking to be quickly sensed, and is attracting attention as a diet tea. The chlorogenic acid contained in the matte itself not only hinders the absorption of fat but also can decompose fat, Effect can be realized.

The above-mentioned "creation" is the roots of Atractylodes japonica belonging to Asteraceae, and it has the effects of perspiration in one room, diuretic, analgesic and dryness, and is used for anorexia, indigestion, gastroenteritis, cold. The above-mentioned effect is to sweat the body, eliminating the unnecessary moisture and improving the body swelling phenomenon, and is effective in weight loss.

The inventors of the present invention derived an optimal combination of herbal raw materials excellent in anti-obesity effect based on clinical therapeutic effects and maximized anti-obesity activity by specifying an extraction method.

The complex extract can be obtained by hot water extraction of green tea, matte and creation, preferably extractable with purified water at 60 ° C to 120 ° C. If the extraction temperature is less than 60 占 폚, the active ingredient contained in the raw material may not be sufficiently extracted, and if it exceeds 120 占 폚, the active ingredient may be destroyed or lost.

The extraction time of the complex extract is preferably from 3 to 10 hours, and if it is less than 3 hours, the active ingredient contained in green tea, matte and creation may not be completely extracted, and if it exceeds 10 hours, desirable.

The complex extract is preferably extracted one to three times repeatedly, and repeatedly extracted twice. When the number of times of extraction is repeated four or more times, the extraction time and the consumption of the extraction solvent are inversely related to the yield of each extract.

The above-mentioned " Cinnamomum cassia " is a stem skin of a camphor tree, an evergreen tree belonging to the genus Camphoraceae. The broiler chickens may vary depending on the area and the origin of the plant, but most of them are tubular or barrel-shaped, the outer surface is dark reddish brown and the inner surface is reddish brown and smooth. Generally, the taste of broiler chicken is sweet, slightly high, fragrant, and differs depending on the region of origin. The broiler chickens are not produced in India, Sri Lanka, China, Japan, and the West Indies.

The broiler system may be extracted with an alcoholic solvent, and the alcoholic solvent may be selected from the group consisting of an anhydrous or a hydrated lower alcohol having 1 to 4 carbon atoms.

The extract may also contain an extract which has been subjected to a conventional purification process. For example, the extract may be subjected to various purification methods such as separation using an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) Lt; RTI ID = 0.0 > fractions. ≪ / RTI >

The anti-obesity composition may comprise a composite extract comprising 8.0 to 40.0 parts by weight of green tea extract, 8.0 to 40.0 parts by weight of mate extract, and 1.0 to 5.0 parts by weight of the extract, and 1.0 to 5.0 parts by weight of the broth extract have.

The above-mentioned anti-obesity composition can control the mixing ratio appropriately in consideration of the working environment and the quality of the final product since the anti-obesity effect derived from the active ingredient of each extract may not be properly implemented when the variation in the mixing ratio is large have. The inventors intend to derive the optimum mixing ratio of the raw materials on the basis of a number of experimental results and maximize the anti-obesity effect of the anti-obesity composition.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating obesity-related metabolic diseases comprising the above anti-obesity composition and a pharmaceutical composition for inhibiting appetite.

The " prevention " means any action that reduces the frequency or extent of the pathological event. Prevention can be complete or partial. In this case, the symptoms due to obesity in the subject may be reduced as compared with the case where the composition is not used.

The term " treatment " means any clinical intervention to alter the natural course of a subject or cell to be treated, and may be performed during or during the course of a clinical pathology. The desired therapeutic effect may be to prevent the occurrence or recurrence of the disease, to alleviate the symptoms, to reduce all direct or indirect pathological consequences of the disease, to prevent metastasis, to reduce the rate of disease progression, Relieving or temporarily alleviating the condition, or improving the prognosis.

The compositions can be administered in the form of oral delivery, parenteral delivery. The composition may be administered systemically or topically, and the administration may include oral administration and parenteral administration. The composition may be formulated with a suitable amount of a pharmaceutically acceptable vehicle or carrier to provide a suitable dosage form.

The composition may further comprise a carrier, an excipient and a diluent used in the preparation of the pharmaceutical composition. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, But are not limited to, cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil.

In addition, the composition may be formulated in the form of oral, granule, tablet, capsule, suspension, emulsion, syrup, aerosol or the like, external preparation, suppository and sterilized injection solution.

The solid preparation for oral administration may be a tablet, a pill, a powder, a granule, a capsule, etc. The solid preparation may be prepared by adding to the compound and its fractions at least one or more excipients such as starch, calcium carbonate, sucrose, lactose , Or gelatin. In addition to the above excipients, lubricants such as magnesium stearate and talc may be used.

The liquid preparation for oral administration may be a suspension, a solution, an emulsion, a syrup, etc. In addition to water and liquid paraffin which are simple diluents, various excipients such as wetting agents, sweeteners, fragrances and preservatives may be used.

The preparation for parenteral administration may be a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized preparation, or a suppository. Examples of the non-aqueous solutions and suspensions may include injectable esters such as propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and ethyl oleate. Examples of the suppository base include witepsol, macrogol, tween 61, cacao butter, laurin, and glycerogelatin.

The composition may be administered in a pharmaceutically effective amount sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the species and severity, age, sex, disease type, Activity, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts.

The composition may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.

The preferred dosage of the composition may vary depending on the condition and the weight of the patient, the severity of the disease, the type of drug, the route of administration and the period of time, and the appropriate total daily dose may be determined by the treatment within the proper medical judgment range , Generally in an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, once or several times a day.

And is not particularly limited as long as it is an object for prevention or treatment of obesity, and any object can be applied. For example, it can be applied to any individual such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cattle, a sheep, a pig, .

According to another aspect of the present invention, there is provided a health functional food for preventing and ameliorating an obesity-related metabolic disease comprising the above-mentioned anti-obesity composition. Also provided is an anti-appetite health functional food comprising the anti-obesity composition.

The health functional food refers to a food prepared and processed by using raw materials or ingredients having useful functions in the human body according to the Act on Health Functional Foods. The functional properties include nutrients for the structure and function of the human body, ≪ / RTI > may be meant to be ingested for the purpose of obtaining a beneficial effect for a health use such as the action.

The above-mentioned health functional foods may contain conventional food additives, and the above-mentioned food additives may be added to the standards and standards of the relevant items in accordance with the General Rules and General Test Methods approved by the Food and Drug Administration, It can be judged whether it is suitable or not.

The food additives described in the above-mentioned Food Additives Code include chemical compounds such as ketones, glycine, potassium citrate, nicotinic acid, and cinnamic acid, natural additives such as persimmon extract, licorice extract, crystalline cellulose, high- A preservative formulation, a tar coloring agent, and the like.

The health functional food may be used for various foods and beverages to prevent or ameliorate obesity. For example, it may be used in various foods, beverages, gums, tea, vitamin complex, health functional supplement, food additive and the like.

The health functional food may be manufactured and processed into any one form selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and rings for the purpose of preventing or improving obesity.

Specifically, the health functional food in the form of tablets can be prepared by granulating the compound, excipient, binder, disintegrant and other additives in a conventional manner, compression-molding the mixture with a lubricant or the like, . The health functional food of the tablet form may contain a mating agent and the like if necessary, and may be sieved to a suitable skin care agent if necessary.

The hard capsule of the above-mentioned capsule type health functional food can be prepared by filling a normal hard capsule with a mixture of the above compound and an additive such as an excipient, or a granular product thereof or a granular product obtained by soaking the product. And the like can be filled in a capsule base such as gelatin. The soft capsule may contain a plasticizer such as glycerin or sorbitol, a coloring agent, a preservative and the like, if necessary.

The above-mentioned ring-form health functional food can be prepared by molding a mixture of the above compound, excipient, binder, disintegrant and the like by an appropriate method. If necessary, the preparation may be mixed with white sugar or other suitable skin care agent or a starch, talc or a suitable substance It is possible that the

The granular health functional food may be prepared by granulating a mixture of the above compound, excipient, binder, disintegrant and the like by a suitable method, and if necessary, may contain a flavoring agent, a mating agent and the like.

Further, the definitions of the above excipients, binders, disintegrants, lubricants, mating agents, flavoring agents and the like are described in documents known in the art, and the functions and the like may be the same or similar.

It will be apparent to those skilled in the art that various changes and modifications may be made thereto without departing from the spirit and scope of the present invention as set forth in the appended claims. It is encompassed in the technical idea of.

The present invention will be further described with reference to the following examples, but it should be apparent that the present invention is not limited by the following examples.

Production Example 1: Preparation of hot water extract

Green tea, matte, and broilers were washed with water, completely dried at room temperature, and pulverized to obtain 300 g of each of the pulverized products.

Each of the pulverized products was subjected to reflux extraction with 2 L of distilled water at a temperature of 100 캜 for 2 hours.

The extract was filtered, concentrated under reduced pressure, and lyophilized to obtain a solid content of each extract.

105 g (yield: 35%) of green tea extract, 90 g (yield: 30%) of mate extract and 93 g (yield: 31%) of the resulting extract were obtained.

Production Example 2: Preparation of Alcohol Extract

The broiler was washed with water, completely dried at room temperature, and pulverized to obtain 300 g of pulverized product.

The pulverized material was refluxed twice with 2 L of 50% ethanol for 2 hours each time.

The extract was filtered, concentrated under reduced pressure, and lyophilized to obtain a solid content of each extract. 23 g of broiler body extract (yield: 7.7%) was obtained.

Examples and Comparative Examples

In order to test the anti-obesity effect of the obtained extracts, the mixed sample as shown in Table 1 was suspended in a 0.5% CMC solution at a dose of 1 g / kg to set Examples and Comparative Examples.

[Content (parts by weight)] division Example 1 Example 2 Comparative Example 1 Comparative Example 2 Comparative Example 3 Comparative Example 4 Comparative Example 5 Green tea extract
(Production Example 1) 76.5 136 272 - - 144 136 Mate extract
(Production Example 1) 76.5 136 - 272 - 144 136 Extract
(Production Example 1) 76.5 17 34 34 - 18 17 Broiler extract
(Production Example 2) 76.5 17 - - 306 - - Broiler extract
(Production Example 1) - - - - - - 17

Experimental Example 1: Inhibition effect on weight gain according to high fat diet

In order to examine the effect of inhibiting weight gain on the samples of the examples and the comparative examples, experiments were conducted in a diet-induced obesity-induced mouse model.

Six - week - old C57BL / 6 mice, which were similar in shape to human obesity, were purchased from the experimental animals.

The animals were kept at a temperature of 22 ± 2 ° C, humidity of 60 ± 10% and fluorescent lights for 12 hours. Animals were housed in boxes of 10 animals per group.

In the normal group, normal diet with 10% of total calories was fed for 12 weeks, and the other groups including the control group were fed with high fat diet with 60% of total calories for 12 weeks in order to induce obesity.

Oral doses per animal were determined at 1 g / kg once a day. Samples of Experimental Example 2 were prepared at concentrations of 0.25, 0.5 and 1 g / kg, and administered orally to each group.

To evaluate the effect of inhibition of weight gain, simvastatin was administered at a dose of 40 mg / kg, once a day.

The simvastatin is a lipid lowering agent of the " HMG-CoA reductase inhibitor " series, which can reduce blood cholesterol production and inhibit the progression of obesity.

Dietary intake and body weight were measured once a week during the experiment. The body weight gain (g) for 12 weeks was divided by the week of the experiment, and the daily weight gain was calculated.

The food efficiency ratio (FER) was calculated by dividing the amount of food taken during the same period by weight gain.

Food efficiency ratio (%) = [weight gain (g) / total dietary intake (g)] X 100

Table 2 shows the weight gain and dietary efficiency of each mouse for 12 weeks.

Experimental group
(content) Initial weight
(g) Final weight
(g) Weight increase
(g) Dietary intake
(g / day) Dietary efficiency
(%) Normal group 21.8 28.6 6.8 2.1 3.9 Control group 21.2 46.4 25.1 2.3 12.8 Example 1
(1 g / kg) 21.4 41.7 16.5 2.3 8.5 Example 2
(0.25 g / kg) 21.3 45.1 23.8 2.2 12.9 Example 2
(0.5 g / kg) 21.1 38.1 17.0 2.1 9.6 Example 2
(1 g / kg) 21.8 36.1 14.4 2.7 6.4 Comparative Example 1
(1 g / kg) 21.2 44.6 23.4 2.5 12.6 Comparative Example 2
(1 g / kg) 21.4 45.0 23.6 2.4 12.5 Comparative Example 3
(1 g / kg) 21.3 45.4 24.1 2.2 13.0 Comparative Example 4
(1 g / kg) 21.3 39.0 18.5 2.1 11.2 Comparative Example 5
(1 g / kg) 21.5 39.3 18.2 2.6 10.4 Simvastatin
(40 mg / kg) 21.1 43.1 22.0 2.1 12.6

The higher the body weight gain than the dietary intake, the higher the amount of calories accumulated in the body fat is judged to be obesity. The higher the dietary efficiency, the more the obesity progressed.

As shown in Table 2, the dietary efficiency of the rest group was higher than that of the normal group, and the obesity of the mice was induced by the diet.

The body weight of the control group was increased by 62.2% as compared with the normal group, but the increase of body weight was suppressed and the diet efficiency was decreased by administering the samples of the examples and the comparative examples.

In addition, the sample of Example 2 was administered by concentration, and the amount of body weight gain was decreased as the administered dose was increased (FIG. 1).

In particular, comparing Example 2 in which broiler meat was extracted with alcohol and Comparative Example 5 in which broiler meat was extracted with hot water showed that compared with Comparative Example 5 containing broiler chick extract obtained by hydrothermal extraction of Example 2 containing broiler extract obtained by alcohol extraction, Respectively.

Experimental Example 2: Inhibition effect of long-term increase by high fat diet

The mice of Experimental Example 1 were used to examine the long-term increase inhibitory effect on the samples of Examples and Comparative Examples.

The mice of Example 1 were fasted for 16 hours, sacrificed after anesthesia via diethyl ether inhalation.

Cardiac blood was drawn using a sterile syringe. The liver was removed, and the blood was removed with physiological saline. The water was removed from the absorbent paper and the weight was measured (Table 3).

Experimental group (content) Liver weight (g) Normal group 1.10 Control group 1.79 Example 1 (1 g / kg) 1.32 Example 2 (0.25 g / kg) 1.78 Example 2 (0.5 g / kg) 1.33 Example 2 (1 g / kg) 1.29 Comparative Example 1 (1 g / kg) 1.62 Comparative Example 2 (1 g / kg) 1.58 Comparative Example 3 (1 g / kg) 1.78 Comparative Example 4 (1 g / kg) 1.52 Comparative Example 5 (1 g / kg) 1.44 Simvastatin (40 mg / kg) 1.60

As shown in Table 3, the weight of the liver was increased by about 62.7% in the control group, The mice of the experimental group to which the samples of the Examples and Comparative Examples were administered had relatively low liver weights as compared with the control group.

In addition, the liver weight of the test group mice administered with 1 g / kg was less than that of the test group administered with 0.25 g / kg in the test group of Example 2.

Experimental Example 3: Improvement of blood lipid level of anti-obesity composition

Blood collected from the mice of Experimental Examples 1 and 2 was used to test the blood lipid-improving effect of the anti-obesity composition on the samples of Examples and Comparative Examples.

Blood collected from the mice was centrifuged at 4 ° C for 15 minutes to obtain serum, which was analyzed as follows.

The measurement kit (Asan, Korea) was used for GOT (glutamic oxalocetic transaminase), GTP (glutamic pyruvate transaminase), TG (triglycerides), TC (tall cholesterol) and HDL (high density lipoprotein) (Table 4). Leptin, insulin, and adiponectin were measured using an ELISA kit (Invitrogen, USA) (Table 5).

Experimental group
(content) GOT
(U / L) GPT
(U / L) TG
(mg / dl) TC
(mg / dl) HDL
(mg / dl) Normal group 127.5 33.3 143.6 92.2 14.4 Control group 233.1 123.3 227.7 199.0 18.9 Example 1
(1 g / kg) 135.1 49.5 164.5 145.5 20.5 Example 2
(0.25 g / kg) 161.3 101.7 203.9 184.3 20.6 Example 2
(0.5 g / kg) 144.4 60.0 167.6 166.9 20.6 Example 2
(1 g / kg) 115.8 44.2 151.2 128.4 18.3 Comparative Example 1
(1 g / kg) 215.6 94.5 198.5 172.2 20.5 Comparative Example 2
(1 g / kg) 204.5 86.5 197.1 168.5 20.1 Comparative Example 3
(1 g / kg) 224.1 105.6 205.4 184.5 20.4 Comparative Example 4
(1 g / kg) 185.1 85.5 178.6 167.3 19.9 Comparative Example 5
(1 g / kg) 175.6 66.5 169.5 164.5 18.5 Simvastatin
(40 mg / kg) 132.7 73.3 157.3 134.7 20.0

GOT and GPT are one of the substances measured in the blood when examining liver function, and the higher the value, the more likely it is obesity.

In addition, elevation of TG and TC in blood is a characteristic phenomenon that occurs in obesity and hyperlipidemia and is associated with various metabolic syndrome and vascular diseases. Therefore, blood TG and TC are important targets in the treatment of obesity and hyperlipemia.

GOT, GPT, TG, TC and HDL values were higher in the control group treated with the high-fat diet compared to the normal group. This suggests that obesity was induced in the mice of the control group that received the high-fat diet compared to the normal diet.

The mice of the experimental group administered with the examples and the comparative samples showed lower values of GOT, GPT, TG, TC and HDL than the control group, suggesting that obesity was improved by the high fat diet.

In addition, the obesity-suppressing effect of the mice to which the sample of the example was administered was superior to the sample of the comparative example.

In particular, comparing Example 2 in which broiler meat was extracted with alcohol and Comparative Example 5 in which broiler meat was extracted with hot water showed that compared with Comparative Example 5 containing broiler chick extract obtained by hydrothermal extraction of Example 2 containing broiler extract obtained by alcohol extraction, Respectively.

Experimental group (content) Leptin (ng / dl) Insulin (ng / dl) Adiponectin (ng / dl) Normal group 2.4 0.46 42.8 Control group 28.9 8.05 57.1 Example 1 (1 g / kg) 13.5 2.54 45.6 Example 2 (0.25 g / kg) 23.9 6.87 46.1 Example 2 (0.5 g / kg) 19.7 2.56 46.0 Example 2 (1 g / kg) 11.6 1.57 37.7 Comparative Example 1 (1 g / kg) 24.5 7.55 50.4 Comparative Example 2 (1 g / kg) 25.4 7.44 49.8 Comparative Example 3 (1 g / kg) 25.6 7.95 55.6 Comparative Example 4 (1 g / kg) 18.9 4.84 47.5 Comparative Example 5 (1 g / kg) 18.5 4.45 46.5 Simvastatin (40 mg / kg) 21.1 4.73 49.4

Leptin, an appetite-suppressing hormone, increases energy expenditure and affects the metabolism of sugar and fat. In the absence of leptin, obesity can be induced. In most obese patients, serum leptin levels are high.

This is related to the leptin resistance rather than the leptin deficiency, because leptin is continuously produced but the signal of leptin is obstructed. Therefore, leptin in the blood is an index of obesity, and leptin levels are similar to the normal group, because the decrease in leptin resistance has an appetite suppressant effect.

Insulin is an anabolic hormone that promotes the use of glucose as an oxidizing substrate and instead acts as a reservoir of amino acids and fatty acids needed for protein and lipid synthesis. Obesity leads to insulin resistance and hyperinsulinemia, leading to an increase in blood insulin. Therefore, blood insulin can be used as an index of obesity.

Adiponectin is a hormone produced in adipocytes and liberated in the blood, which is known to play a role in suppressing obesity.

Adiponectin increases the sensitivity of insulin in muscle and liver tissue and increases fat oxidation and reduces body weight. Adiponectin can be elevated depending on body weight and body fat mass.

As shown in Table 5, the levels of leptin, insulin, and adiponectin were higher in the control group treated with the high-fat diet than the normal group. This suggests that obesity was induced in mice of the control group with high fat diet compared to the normal diet group, suggesting that leptin resistance is formed in the control group as compared with the normal group.

The mice of the experimental group administered with the examples and the comparative samples showed lower values of leptin, insulin and adiponectin than the control group, suggesting the improvement of obesity due to the fat diet.

In particular, the level of leptin was reduced by more than half that of the control group, suggesting that leptin resistance by the high concentration of leptin in the blood is alleviated and appetite suppression may be induced.

In addition, the obesity-suppressing effect of the mice to which the sample of the example was administered was superior to the sample of the comparative example.

Experimental Example 4: Long-term lipid improvement effect of anti-obesity composition

The liver obtained from the mice of Experimental Examples 1 and 2 was used to examine the long-term lipid-improving effect of the anti-obesity composition on the samples of Examples and Comparative Examples.

0.2 g of liver obtained from mice were homogenized with 0.1 ml of PBS. 3 ml of chloroform: methanol (2: 1, v / v) mixed solution was added and the mixture was extracted for 1 hour and centrifuged.

The centrifuged lower layer was dried and TG and TC were measured in the same manner as in Experimental Example 3 (Table 6).

Experimental group (content) TG (mg / dl) TC (mg / dl) Normal group 155.3 11.1 Control group 557.3 46.3 Example 1 (1 g / kg) 162.5 22.5 Example 2 (0.25 g / kg) 472.0 44.3 Example 2 (0.5 g / kg) 243.7 18.8 Example 2 (1 g / kg) 151.3 12.9 Comparative Example 1 (1 g / kg) 354.5 30.5 Comparative Example 2 (1 g / kg) 298.5 28.4 Comparative Example 3 (1 g / kg) 435.5 38.2 Comparative Example 4 (1 g / kg) 182.5 17.8 Comparative Example 5 (1 g / kg) 178.4 16.5 Simvastatin (40 mg / kg) 381.7 32.4

As shown in Table 6, the content of TG in the liver tissue was increased by about 258.9% in the control group and increased by 317.1% in the control group.

The higher TG and TC contents in the liver tissues than in the normal group means that the fat accumulation is high and progress to obesity.

The low TG and TC contents in the liver tissue despite the high fat diet means that the fat accumulation by the diet is small and this means that it has the effect of inhibiting the progression to obesity by the sample. TG and TC contents in the liver tissues of mice in the experimental group administered with the sample were lower than those of the control group.

Also, in the experimental group of Example 2, the TG and TC contents in the liver tissues of the mice to which 1 g / kg was administered were lower than those of the mice to which 0.25 g / kg was administered, Suggesting that the effect is excellent.

With reference to Experimental Examples 2 to 4, the anti-obesity composition of the present invention can effectively improve not only obesity but also fatty liver symptoms.

Fatty liver disease, one of the diseases related to obesity, is caused by the accumulation of liver fat, which is caused by excessive production of fat, which in turn causes liver damage by lipid peroxidation.

Increase in blood GOT and GPT, increase in liver weight and increase of TC and TG in liver tissue suggest that non - alcoholic fatty liver was induced by high fat diet.

In addition, as described in Experimental Examples 2 to 4, the increase in blood GOT and GPT, the increase in liver weight, and the increase in TC and TG in liver tissue were suppressed by the examples and the comparative samples, which means that the fatty liver symptoms were improved.

The present invention has been shown to reduce body weight by the anti-obesity composition in the obese-induced mouse model, and to decrease blood GOT, GPT, TG and TC. In addition, liver weight, liver tissue TG and TC were decreased, and blood leptin, insulin and adiponectin concentrations were decreased.

The results suggest that the anti-obesity composition improves the symptoms of obesity, hyperlipidemia and fatty liver induced by high fat diet, and can be utilized as a medicine or functional food for anti-obesity purpose.

It will be understood by those skilled in the art that the foregoing description of the present invention is for illustrative purposes only and that those of ordinary skill in the art can readily understand that various changes and modifications may be made without departing from the spirit or essential characteristics of the present invention. will be. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. For example, each component described as a single entity may be distributed and implemented, and components described as being distributed may also be implemented in a combined form.

The scope of the present invention is defined by the appended claims, and all changes or modifications derived from the meaning and scope of the claims and their equivalents should be construed as being included within the scope of the present invention.

Claims (11)

A green tea extract, a mate extract, and a resulting extract; And
A broiler chick extract as an active ingredient,
Wherein said complex extract is hydrolyzed and said broiler chick extract is extracted with an alcoholic solvent. The method according to claim 1,
Wherein said complex extract is hydrothermally extracted at 60 to < RTI ID = 0.0 > 120 C. < / RTI > delete The method according to claim 1,
Wherein the alcoholic solvent is one or more selected from the group consisting of an anhydrous or hydrated lower alcohol having 1 to 4 carbon atoms. The method according to claim 1,
Wherein said complex extract comprises 8.0 to 40.0 parts by weight of green tea extract, 8.0 to 40.0 parts by weight of mate extract, and 1.0 to 5.0 parts by weight of the resulting extract. 6. The method of claim 5,
1.0 to 5.0 parts by weight of said broiler extract. A pharmaceutical composition for preventing or treating obesity-related metabolic diseases comprising the composition of any one of claims 1, 2, and 4 to 6. 8. The method of claim 7,
Wherein said obesity-related metabolic disease is stroke, hyperlipidemia, arteriosclerosis, cardiovascular disease or nonalcoholic fatty liver. A pharmaceutical composition for an appetite suppressing composition comprising the composition of any one of claims 1, 2, and 4 to 6. A health functional food for preventing or ameliorating obesity-related metabolic diseases comprising the composition of any one of claims 1, 2, and 4 to 6. 8. A health food having an appetite suppressing effect comprising the composition of any one of claims 1, 2, and 4 to 6.

Images